Xiang Peng

1.3k total citations
22 papers, 986 citations indexed

About

Xiang Peng is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xiang Peng has authored 22 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Xiang Peng's work include Cancer, Hypoxia, and Metabolism (9 papers), TGF-β signaling in diseases (5 papers) and Bone health and treatments (4 papers). Xiang Peng is often cited by papers focused on Cancer, Hypoxia, and Metabolism (9 papers), TGF-β signaling in diseases (5 papers) and Bone health and treatments (4 papers). Xiang Peng collaborates with scholars based in China, United States and France. Xiang Peng's co-authors include Maria Niewolna, Khalid S. Mohammad, Pierrick G.J. Fournier, Theresa A. Guise, Christopher R. McKenna, John M. Chirgwin, Lauren K. Dunn, Holly W. Davis, Alain Mauviel and Delphine Javelaud and has published in prestigious journals such as Gastroenterology, PLoS ONE and Cancer Cell.

In The Last Decade

Xiang Peng

22 papers receiving 976 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiang Peng China 13 594 453 308 177 88 22 986
Sílvia Regina Caminada de Toledo Brazil 23 654 1.1× 290 0.6× 287 0.9× 186 1.1× 154 1.8× 68 1.4k
Martina Storz Switzerland 17 510 0.9× 326 0.7× 255 0.8× 327 1.8× 94 1.1× 23 935
Kelly J. Gordon United States 7 701 1.2× 315 0.7× 156 0.5× 121 0.7× 82 0.9× 10 1.0k
Marcela F. Bolontrade Argentina 18 463 0.8× 309 0.7× 249 0.8× 153 0.9× 120 1.4× 28 927
JuanJuan Yin United States 6 605 1.0× 720 1.6× 290 0.9× 226 1.3× 75 0.9× 9 1.1k
Gabrielle S. Wong United States 13 448 0.8× 394 0.9× 226 0.7× 151 0.9× 196 2.2× 17 916
Eva Allonca Spain 23 570 1.0× 410 0.9× 269 0.9× 158 0.9× 144 1.6× 46 1.1k
Eva Cubillo Spain 9 794 1.3× 528 1.2× 259 0.8× 115 0.6× 58 0.7× 10 1.1k
Signe Ingvarsen Denmark 16 329 0.6× 283 0.6× 351 1.1× 85 0.5× 77 0.9× 21 817
L Martín United Kingdom 10 682 1.1× 355 0.8× 446 1.4× 204 1.2× 149 1.7× 14 1.1k

Countries citing papers authored by Xiang Peng

Since Specialization
Citations

This map shows the geographic impact of Xiang Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiang Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiang Peng more than expected).

Fields of papers citing papers by Xiang Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiang Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiang Peng. The network helps show where Xiang Peng may publish in the future.

Co-authorship network of co-authors of Xiang Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiang Peng. A scholar is included among the top collaborators of Xiang Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiang Peng. Xiang Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qiu, Heping, Fei Liu, Mei Qiu, Juliang Yang, & Xiang Peng. (2025). Monotropein attenuates renal cell carcinoma cell progression and M2 macrophage polarization by weakening NF-κB. International Urology and Nephrology. 57(6). 1785–1795. 1 indexed citations
2.
Wang, Jingsong, Xiang Peng, Zhen Ye, et al.. (2024). Medical therapy has similar hemostatic efficacy with endoscopic treatment for PUB patients with adherent clot (FIIb ulcers). Surgical Endoscopy. 38(4). 1791–1806. 1 indexed citations
3.
Peng, Xiang, Jinchao Chen, Shuanghe Peng, et al.. (2019). Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients. Journal of Medical Genetics. 56(6). 380–387. 10 indexed citations
4.
Zhou, Bowen, Jiangyi Wang, Shengjie Liu, et al.. (2019). Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients. Frontiers in Oncology. 9. 1037–1037. 13 indexed citations
5.
Ma, Kaifang, Baoan Hong, Jingcheng Zhou, et al.. (2019). The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients. Frontiers in Oncology. 9. 1122–1122. 10 indexed citations
6.
7.
Zhi, Min, Min Zhang, Xiaodong Jiang, et al.. (2019). Su1916 – Absence of Perianal Symptoms Does Not Mean No Perianal Fistula in Crohn’s Disease: Base on Mri Examination. Gastroenterology. 156(6). S–659. 2 indexed citations
8.
9.
Hong, Baoan, Lin Cai, Jiangyi Wang, et al.. (2018). Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features. Clinical Genitourinary Cancer. 17(2). 97–104.e1. 7 indexed citations
10.
Liu, Shengjie, Jiangyi Wang, Shuanghe Peng, et al.. (2018). Genotype and phenotype correlation in von Hippel–Lindau disease based on alteration of the HIF-α binding site in VHL protein. Genetics in Medicine. 20(10). 1266–1273. 31 indexed citations
11.
Wang, Jiangyi, Shuanghe Peng, Teng Li, et al.. (2018). Risk factors for survival in patients with von Hippel-Lindau disease. Journal of Medical Genetics. 55(5). 322–328. 23 indexed citations
12.
Wang, Jiangyi, Shuanghe Peng, Xianghui Ning, et al.. (2017). Shorter telomere length increases age‐related tumor risks in von Hippel‐Lindau disease patients. Cancer Medicine. 6(9). 2131–2141. 15 indexed citations
13.
Juárez, Patricia, Pierrick G.J. Fournier, Khalid S. Mohammad, et al.. (2017). Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget. 8(49). 86447–86462. 33 indexed citations
14.
Xiao, Li, Xiang Peng, Fuyou Liu, et al.. (2015). AKT regulation of mesothelial-to-mesenchymal transition in peritoneal dialysis is modulated by smurf2 and deubiquitinating enzyme USP4. BMC Cell Biology. 16(1). 7–7. 24 indexed citations
15.
Zuo, Jianhong, Meiling Wen, Mingsheng Lei, et al.. (2015). MiR‐210 Links Hypoxia With Cell Proliferation Regulation in Human Laryngocarcinoma Cancer. Journal of Cellular Biochemistry. 116(6). 1039–1049. 35 indexed citations
16.
Fournier, Pierrick G.J., Patricia Juárez, Guanglong Jiang, et al.. (2015). The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell. 27(6). 809–821. 162 indexed citations
17.
Juárez, Patricia, Khalid S. Mohammad, Juan Juan Yin, et al.. (2012). Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases. Cancer Research. 72(23). 6247–6256. 64 indexed citations
18.
Mohammad, Khalid S., Delphine Javelaud, Pierrick G.J. Fournier, et al.. (2010). TGF-β-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Research. 71(1). 175–184. 185 indexed citations
19.
Mohammad, Khalid S., Guive Balooch, Elizabeth G. Stebbins, et al.. (2009). Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone. PLoS ONE. 4(4). e5275–e5275. 146 indexed citations
20.
Dunn, Lauren K., Khalid S. Mohammad, Pierrick G.J. Fournier, et al.. (2009). Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PLoS ONE. 4(9). e6896–e6896. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sílvia Regina Caminada de Toledo Breakdown of academic impact, for papers by Martina Storz Breakdown of academic impact, for papers by Kelly J. Gordon Breakdown of academic impact, for papers by Marcela F. Bolontrade Breakdown of academic impact, for papers by JuanJuan Yin Breakdown of academic impact, for papers by Gabrielle S. Wong Breakdown of academic impact, for papers by Eva Allonca Breakdown of academic impact, for papers by Eva Cubillo Breakdown of academic impact, for papers by Signe Ingvarsen Breakdown of academic impact, for papers by L Martín
Rankless by CCL
2026